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decreased risk of mortality imparted by beta-blockade (approximately
35%) [2] must be considered. The power of these ﬁndings are limited by
thesmall numberof patientswithmoderate airways reversibility (n=4).
However,we take some reassurance from the goodproportionof patients
diagnosed with asthma recruited to the study. Despite the limitation, we
believe our study provides important hypothesis-generating data that
contributes to a paucity of relevant literature in this area. A larger
long-term study is required to provide deﬁnitive data regarding the effect
of nebivolol on CHF patients withmoderate reversibility airways disease.
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Chagas disease remains an important health problem with cardiac
involvementbeing amajorcharacteristic of thedisease. Dysautonomia is
an independent phenomenon, whichmay contribute to the high rate of
sudden death in this disease [1].
Neurotrophins are a family of proteins that have been implicated in
important cardiovascular functions [2]. Brain-derived neurotrophic
factor (BDNF) is themostwidely distributed neurotrophin in the central
nervous system [3]. Recently, increased levels of BDNFwere observed in
patients with Chagas disease, a phenomenon attributed both to
inﬂammatory processes and cardiac autonomic dysfunction [4].
Aerobic exercise training (AET) has been found to promote
neurogenesis and to elevate BDNF in animal experiments and in humans
[5]. Nevertheless, the underlying mechanisms of this phenomenon are
unknown [6].
Recently, AET was shown to produce marked improvements in both
functional capacity (FC) andhealth-related quality of life inChagasheart
disease (CHD) patients [7]. In the present study, we investigated the
effect of AET on serum BDNF levels and the relationship of AET and
serum BDNF with cardiac autonomic modulation in patients with CHD.
To be eligible for the study, the patient had to have a diagnosis of
chronic CHD and left ventricular systolic dysfunction. Patients whowere
physically active were excluded from the study. All of the patients were
clinically stable for at least 3 months, were in sinus rhythm and were
currently being treated by standard medical therapy.
At the time of enrolment, each patient underwent: a clinical
examination; laboratory tests; 12-lead ECG; a comprehensive Doppler
echocardiogram; and symptom-limited exercise testing using the
standard Bruce protocol on a treadmill (Digistress Pulsar, Micromed,
Brasilia, Brazil). The patient's heart rate (HR) was determined from the
ECG recording, and the chronotropic response was recorded as the
percentage of age-predicted heart rate achieved according to Astrand's
formula (220-age) at peak exercise. At baseline and after 12 weeks all
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Table 1
Association between the improvement of the 6MWD and BDNF levels with baseline
parameters.
Variables Δ 6MWD, m Δ BDNF, pg/ml
rs p value rs p value
Δ BDNF, pg/ml 0.673 0.002⁎ – –
BDNF, pg/ml −0.739 0.000⁎
% Maximal age-predicted HR 0.527 0.020⁎ 0.100 0.684
LVEF, % 0.112 0.648 0.093 0.704
LVDd, mm 0.061 0.804 −0.031 0.900
BNP, pg/ml −0.221 0.362 −0.188 0.441
SDNN, ms 0.555 0.014⁎ 0.646 0.003⁎
rMSSD, ms 0.558 0.013⁎ 0.672 0.002⁎
6MWD, six-minute walk distance; BDNF, brain derived neurotrophic factor; HR, heart
rate; LVEF, left ventricular ejection fraction; LVDd, left ventricular end-diastolic
diameter; BNP, brain natriuretic peptide; SDNN, standard deviation of normal NN
intervals; rMSSD, root mean square of successive difference in normal RR intervals.
⁎ pb0.05.
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patients underwent: a six-minute walk test according to a standardised
protocol [7], with six-minute walk distance (6MWD) utilized for
evaluation of the FC; submitted samples of venous blood for analyses
of BDNF concentrations, according to the procedure supplied by the
manufacturer using sandwich ELISA Kits for BDNF (DuoSet, R&D
Systems, Minneapolis, MN, USA); and were subjected to 24-hour Holter
monitoring for analyses of heart rate variability (HRV). The following
time-domain HRV indexes were calculated: standard deviation of RR
intervals (SDNN) and square root of the mean of the sum of squares of
differences between adjacent RR intervals (rMSSD).
Patients participated in a supervised AET consisting of 3 sessions per
week, on alternate days, for a total of 36 sessions in 12 weeks [7]. The
exercise intensity was based on the HR peak reached at the exercise test
and calculated by the Karvonen formula: {(maximal HR−HR at
rest)×50 to 70%+HR at rest}.
Statistical analysis was performed using SPSS software version 13.0
(SPSS Inc., Chicago, Illinois). Data were expressed as mean±SD or
median and interquartile ranges, as appropriate. To analyse changes in
continuous variables at 12 weeks from baseline, a paired Student's t-test
or a paired Wilcoxon signed rank test was used, as appropriate.
Fig. 1. Association between the variation of the 6MWD before and after the AET and ΔBDNF levels (A), baseline values of the BDNF (B), % of maximal age-predicted HR during
symptom-limited exercise test (C), and HRV indexes rMSSD (D). Association between ΔBDNF levels before and after the AET and HRV indexes SDNN (E) and rMSSD (F).
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Spearman's correlation coefﬁcient was employed to measure correlation
between variables. Receiver–operator curve analysis identiﬁed the best
cut-off value of delta BDNF and basal SDNN values for identifying
improvement of the least 50 m in 6MWD after AET.
Nineteen patients (10 male) completed the study, with mean age of
48.5±8.7 years, left ventricular ejection fraction of 36.9±7.4%, and left
ventricular end-diastolic diameter of 63.7±5.9 mm. After the 12-week
study changes were observed in the 6MWD (Δ median=83.5 m, p=
0.001), HR at rest (Δ=−6.9±8.8 bpm, p=0.002), and chronotropic
response (Δ=7.4±9 bpm, p=0.002).
The associations among the variation of 6MWD and BDNF serum
levels and baseline measurements are shown in Table 1. The improve-
ment of the 6MWD (Δ) exhibited a positive relationship with the
changes in BDNF (Δ) (Fig. 1A). At baseline, the relationship between the
6MWDwas negativewith BDNF (Fig. 1B) and positive with chronotropic
response (Fig. 1C) and HRV indexes (Fig. 1D). The increase of BDNF was
signiﬁcantly correlated with both basal SDNN and rMSSD (Fig. 1E and F,
respectively).
Both basal SDNNvalues and the change of BDNF levelswere highly
predictive of an improvement of 50 m or more in the 6MWD after
AET. The area under the ROC curve was 0.91 (SE=0.068, p=0.005)
for BDNF and 0.84 (SE=0.090, p=0.016) for SDNN. Further, a
positive change in BDNF levels was observed only in patients with a
signiﬁcant increase (N50 m) in their 6MWD, indicating that a positive
change in BDNF is 100% speciﬁc for a beneﬁcial response of the
6MWD after AET (Fig. 2).
To the best of our knowledge, this study is the ﬁrst to demonstrate
the relationship between FC, BDNF levels and autonomic modulation in
patients with CHD. The main ﬁndings of this study are as follows: (I) a
better performance in the 6MWD is closely related to the increase in
serum levels of BDNF; and (II) the increase of both the 6MWD and the
levels of BDNF is detected mainly in patients in whom autonomic
function was preserved.
BDNF can be inﬂuenced by several external stimuli [6]. Studies
have demonstrated that short episodes of high intensity exercise may
transiently increase serum BDNF [8]. Nevertheless, the effect of
physical training on BDNF concentration is unknown and previous
studies demonstrated contradictory results [5,6]. Zoladz et al. [9]
evaluating 13 young healthy physically active men revealed a
signiﬁcant increase in the levels of BDNF as well as in FC following
5 weeks of AET. On the other hand, no changes in serum BDNF levels
were observed in sedentary young adults after 8 weeks of AET in
comparison with the inactive group, although FC levels increased
signiﬁcantly of the study participants [10].
In individuals with multiple sclerosis, a signiﬁcant increase in BDNF
levels after exercise returned to baseline levels at week 8, suggesting
once the subject becomes used to this exercise, BDNF levels return to
baseline levels [11]. These controversial results may occur due to
different protocols of training, and uncertain metabolic responses to
exercises between healthy and sick subjects [6].
In our study, the increase in BDNFafter AETwas strongly related to the
improvementof the6MWD,which suggests that BDNFup-regulationmay
have a physiopathological role in the improvement of FC. Neuroendo-
crine andmetabolic peripheral effects of BDNF [12]mayexplain its value
on the improvement of FC with exercise. In particular, our patient who
had lower basal levels of BDNF presented an important increase in the
6MWD, suggesting that they have less severe heart disease and may
respond better to AET.
Additionally, we found that the increase of BDNF with exercise was
evident in the patients with preserved autonomic function. Abnormal
autonomic modulation with reduced vagal HRV indexes is a typical
feature of CHD [13]. Our previous studies in CHD suggest that the
autonomic dysfunction plays a role in themodiﬁcation of the response to
exercise. In this setting, the relationship between the level of physical
activity and the increased vagal-related HRV is disrupted [14]. A possible
link among all of these processes in CHD is the presence of circulating
autoantibodies against M2 muscarinic receptors with in vivo antagonist
effects, which are negatively correlated with vagal HRV indexes and
chronotropic incompetence [15].
Therefore, our results demonstrate a previously unrecognised
relationship among the improvement in FC after exercise training,
BDNF levels and autonomic modulation in CHD. The improvement in FC
wasassociatedwithpreservedautonomic function and lowbasal levels of
BDNF. The integrity of the heart autonomic nervous system may play a
role in the adequate response to AET in these patients. Further studies are
necessary to better understand the complex relationship among physical
activity, BDNF levels and autonomic function.
The authors of this manuscript have certiﬁed that they comply with
the Principles of Ethical Publishing in the International Journal of
Cardiology.
References
[1] Ribeiro AL, Nunes MP, Teixeira MM, Rocha MO. Diagnosis andmanagement of Chagas
disease and cardiomyopathy. Nat Rev Cardiol Oct 2012;9(10):576–89.
[2] Caporali A, Emanueli C. Cardiovascular actions of neurotrophins. Physiol Rev Jan
2009;89(1):279–308.
[3] Teixeira AL, Barbosa IG, Diniz BS, Kummer A. Circulating levels of brain-derived
neurotrophic factor: correlation with mood, cognition and motor function. Biomark
Med Dec 2010;4(6):871–87.
[4] Martinelli PM, da Costa Rocha MO, Teixeira AL, do Carmo Pereira Nunes M, da Silva
Camargos ER. Brain-derived neurotrophic factor is up regulated in chronic Chagas
disease. Int J Cardiol Jun 2 2011;49(2):277–8.
[5] Zoladz JA, Pilc A. The effect of physical activity on the brain derived neurotrophic
factor: from animal to human studies. J Physiol Pharmacol Oct 2010;61(5):533–41.
[6] Knaepen K, Goekint M, Heyman EM, Meeusen R. Neuroplasticity—exercise-induced
response of peripheral brain-derived neurotrophic factor: a systematic review of
experimental studies in human subjects. Sports Med 2010;40(9):765–801.
[7] Lima MM, Rocha MO, Nunes MC, et al. A randomized trial of the effects of exercise
training in Chagas cardiomyopathy. Eur J Heart Fail Aug 2010;12(8):866–73.
[8] Tang SW, Chu E, Hui T, Helmeste D, Law C. Inﬂuence of exercise on serum brain-
derived neurotrophic factor concentrations in healthy human subjects. Neurosci Lett
Jan 24 2008;431(1):62–5.
[9] Zoladz JA, Pilc A, Majerczak J, Grandys M, Zapart-Bukowska J, Duda K. Endurance
training increases plasma brain-derived neurotrophic factor concentration in young
healthy men. J Physiol Pharmacol Dec 2008;59(Suppl 7):119–32.
[10] Goekint M, Roelands B, De Pauw K, Knaepen K, Bos I, Meeusen R. Does a period of
detraining cause a decrease in serum brain-derived neurotrophic factor? Neurosci
Lett Dec 17 2010;486(3):146–9.
[11] Castellano V, White LJ. Serum brain-derived neurotrophic factor response to aerobic
exercise in multiple sclerosis. J Neurol Sci Jun 15 2008;269(1–2):85–91.
[12] Nakagawa T, Ono-Kishino M, Sugaru E, Yamanaka M, Taiji M, Noguchi H. Brain-
derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in
diabetic mice. Diabetes Metab Res Rev May–Jun 2002;8(3):185–91.
Fig. 2. Accuracy of the change in BDNF levels and basal SDNN values in predicting an
improvement of at least 50 m of 6MWD after AET, as evaluated by the ROC Curve.
2365Letters to the Editor
[13] Ribeiro AL, Gimenez LE, Hernandez CC, et al. Early occurrence of anti-muscarinic
autoantibodies and abnormal vagal modulation in Chagas disease. Int J Cardiol Apr
12 2007;117(1):59–63.
[14] Sousa L, Rocha MO, Britto RR, Lombardi F, Ribeiro AL. Chagas disease alters the
relationship between heart rate variability and daily physical activity. Int J Cardiol Jun
26 2009;135(2):257–9.
[15] Talvani A, Rocha MO, Ribeiro AL, Borda E, Sterin-Borda L, Teixeira MM. Levels of
anti-M2 and anti-beta1 autoantibodies do not correlate with the degree of heart
dysfunction in Chagas' heart disease. Microbes Infect Aug 2006;8(9–
10):2459–64.
0167-5273/$ – see front matter © 2012 Elsevier Ireland Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ijcard.2012.11.055
Acceptable transfer delay to primary PCI vs on-site ﬁbrinolysis for STEMI — Can ECG
parameters help clinical judgment?
Cheuk-Kit Wong ⁎
Department of Cardiology, Dunedin School of Medicine, University of Otago, Dunedin Public Hospital, Dunedin, New Zealand
a r t i c l e i n f o
Article history:
Received 23 October 2012
Accepted 10 November 2012






Timely primary percutaneous coronary intervention (PCI) is the
reperfusion strategy for STEMI, but probably less than half of the
hospitals worldwide have a 24/7 PCI service. Randomized trials suggest
that transfer for primary PCI is superior to onsite ﬁbrinolytic therapy [1].
The generalizability of these ﬁndings is unclear because door-to-balloon
times are usually shorter in trials than in practice.
In the2011 report fromtheNational Registry ofMyocardial Infarction
(NRMI) 2,3,4,5 registries involving 11,662 patients with transferral for
PCI and 95,366 patients with onsite ﬁbrinolysis, propensity score
matched analysis (9506 pairs matched for patient, hospital and
insurance parameters) suggests equipoise of in-hospital mortality if
the PCI-related delay is 2 h (121 min). PCI-related delay is the difference
between door-to-balloon time (time duration between the ﬁrst hospital
arrival to balloon inﬂation) for PCI and door-to-needle time for
ﬁbrinolysis. However, almost half of the patients have delays longer
than 2 h [2].
STEMI is heterogeneous in respect of patient characteristics,
potential infarct size, and stage of infarct evolution. A meta-analysis
[3] of randomized trials (mostly performed in 1990s) reported a
negative linear relationship between absolute reduction of mortality
and PCI-related delay, so that for high-risk patients beneﬁt of primary
PCI over ﬁbrinolysis can be seen with delay of over 3 h! This approach
has 2 caveats — the low incidence of “rescue PCI” for unsuccessful
ﬁbrinolysis in the 1990s; and that survival beneﬁt could have
predominated in older patients who have higher mortality and
post-ﬁbrinolysis bleeding.
Most guidelines recommend a ﬁrst clinical contact to device/balloon
time within 90–120 min [4,5]. The 2012 European guidelines [4]
continue from their previous version [6] to recommend the 120 minute
cut-point as acceptable (Class 1) but also recommend consideration for
ﬁbrinolysis for the earlier 90 minute cut-point if the patient presents
early and has large STEMI territory with low bleeding risks (Class 2a).
The 2011 ACCF/AHA/SCAI Guideline recommends that primary
PCI should be performed in patients with STEMI presenting to a
hospital without PCI capability within 120 min of ﬁrst medical contact
(Class 1) [7].
Time duration from symptoms onset is the traditional parameter to
reﬂect STEMI evolution with presentations within 12 h considered
eligible for reperfusion. Gersh et al. [8] hypothesized a curve relating
the duration of symptoms before reperfusion to reduction in mortality
and extent of myocardial salvage. During the ﬁrst 2 to 3 h after
symptom onset, the curve has a steep slope where beneﬁt of
reperfusion is time dependent (“Time is Muscle”). Subsequently, the
curve has a gentle slope where beneﬁt is decreasing much more slowly
over time. Based on this curve longer PCI-related delay will be more
acceptable in later-presenting than in earlier-presenting patients. The
2012 European Guidelines [4] describe new “quality indicators” that “in
patients presenting early, with a large amount of myocardium at risk,
the delay between ﬁrst medical contact and wire passage of PCI should
bewithin 60 min”. However, whether the time duration from symptom
onset is the best parameter to reﬂect STEMI progression is open to
question.
In the previous report from the NRMI 2,3,4 registries involving
192,509 patients [9], an adjusted analysis was made to discern the
PCI-related delay thatmortality beneﬁt of PCI over ﬁbrinolysis would be
lost. The NRMI database is much larger than others such as the 1053
patient Vienna database [10] and the 1832 patient Quebec database [11].
Despite that statistical adjustments are limited by their underlying
assumptions, the observational NRMI data examining equipoise of
mortality are unique and illustrate the inherent heterogeneity of STEMIs
according to the time from symptom onset (pre-hospital/presentation
delay), age and infarct location. The PCI-related delay that gives equal
mortality betweenprimary PCI andﬁbrinolysis is consistently shorter by
at least 1 h for younger (agedb65) than for older patients, andbyat least
half an hour for anterior than for non-anterior STEMI, regardless of the
pre-hospital delay (Table 1).
The PCI-related delay for equipoise of mortality is shorter in
patients presenting≤120 min from symptom onset than in
later-presenting patients. However, the ﬁgures are almost equal
for young patients with anterior STEMI (bothb45 min) and old
patients with non-anterior STEMI (bothN165 min, Table 1). Infarct
evolution is slower if collaterals pre-exist, as in older patients with
longer-standing coronary disease. Other factors including
pre-conditioning and spontaneous infarct-artery recanalizations
also slow progression [8,12]. Should ECG parameters of infarct
progression supersede the time duration from symptoms onset in
guiding management?
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